RCS-8

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 464379212

| IUPAC_name = 2-(2-Methoxyphenyl)-1-[1-(2-cyclohexylethyl)indol-3-yl]ethanone

| image = RCS-8.svg

| image_class = skin-invert-image

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA = Schedule II

| legal_DE = NpSG

| legal_UK = Class B

| legal_US = Schedule I

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|SciFinder}}

| CAS_number = 1345970-42-4

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 11030I5W3R

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 24751863

| C=25 | H=29 | N=1 | O=2

| smiles = COc1ccccc1CC(=O)c2cn(c3c2cccc3)CCC4CCCCC4

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C25H29NO2/c1-28-25-14-8-5-11-20(25)17-24(27)22-18-26(23-13-7-6-12-21(22)23)16-15-19-9-3-2-4-10-19/h5-8,11-14,18-19H,2-4,9-10,15-17H2,1H3

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = BSQFBMXCQIKYNI-UHFFFAOYSA-N

}}

RCS-8 (also known as 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole, SR-18, and BTM-8) is a synthetic cannabinoid that has been found as an ingredient of "herbal" synthetic cannabis blends. It can be described as an analogue of JWH-250 with the 1-pentyl group replaced by 1-(2-cyclohexylethyl), and can be expected to be less potent than JWH-250 (cf. JWH-007 and its cyclohexylethyl analogue).{{Cite journal | vauthors = Huffman JW, Dai D, Martin BR, Compton DR | title = Design, Synthesis and Pharmacology of Cannabimimetic Indoles | doi = 10.1016/S0960-894X(01)80155-4 | journal = Bioorganic & Medicinal Chemistry Letters | volume = 4 | issue = 4 | pages = 563–566 | year = 1994 }} Despite not having been reported in the scientific or patent literature as yet, reputed recreational use of RCS-8 in the United States has led to it being specifically listed in a proposed 2011 amendment to the Controlled Substances Act, aiming to add a number of synthetic drugs into Schedule I.[http://www.gpo.gov/fdsys/pkg/BILLS-112hr1254ih/pdf/BILLS-112hr1254ih.pdf Synthetic Drug Control Act of 2011] In addition, all CB₁ receptor agonists of the 3-phenylacetylindole class such as RCS-8 are Schedule I Controlled Substances.{{UnitedStatesCode2|21|812|Schedules of controlled substances}}